Heparin, Platelet Aggregation, Neutrophils, and Cardiopulmonary Bypass

Belcher, Philip R.; Muriithi, Elijah W.; Milne, Elodie M.; Wanikiat, Payong; Wheatley, David J.; Armstrong, Roma A.

doi:10.1016/s0049-3848(99)00243-1

Cited by 31 publications

(29 citation statements)

References 21 publications

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…23 Heparin was preferred as a blood anticoagulant for the present study, as the use of a non-standard blood collection tube may complicate the clinical application of impedance aggregometry. Although in vivo heparinization was shown to impair macroaggregation in WBA, the study of Belcher et al 24 offered evidence that ex vivo heparinization with low doses of heparin does not affect macroaggregation significantly.…”

Section: Discussionmentioning

confidence: 99%

Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry

Rahe‐Meyer¹,

Winterhalter²,

Boden³

et al. 2009

Acta Anaesthesiol Scand

130

106

View full text Add to dashboard Cite

Background: Platelet dysfunction contributes to the pathophysiology of bleeding complications during and after cardiac surgery. In most surgical institutions, no peri-operative pointof-care monitoring of platelet function is used. We evaluated the usefulness of the Multiplate s platelet function analyser based on impedance aggregometry for identifying groups of patients at a high risk of transfusion of platelet concentrates (PC). Methods: Platelet function parameters were determined in 60 patients before and after routine cardiac surgery. Impedance aggregometry measurements were performed on Multiplate s using ADP (ADPtest), collagen (COLtest) and thrombin receptor activating peptide (TRAPtest) as platelet activators. The correlations between the aggregometry results and the transfusion of PC were calculated. The results of the aggregation tests were also divided into tertiles and the differences in PC transfusion between the low and the high tertile were assessed.

show abstract

Section: Discussionmentioning

confidence: 99%

Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry

Rahe‐Meyer¹,

Winterhalter²,

Boden³

et al. 2009

Acta Anaesthesiol Scand

130

106

View full text Add to dashboard Cite

show abstract

“…Platelets sequestered in the body during extracorporeal circulation later return to the circulation and have a normal life span. In theory, the inhibitory effect of heparin on platelet aggregation (Belcher et al 2000, Muriithi et al 2000a) may preserve platelets.…”

Section: Cardiopulmonary Bypass and Effects Of Heparinization On Platmentioning

confidence: 99%

Post‐operative volume therapy in cardiac surgery: effects on hemostatic and circulatory variables

Schramko¹

2011

Acta Anaesthesiol Scand

View full text Add to dashboard Cite

“…UFH is highly antigenic, provoking an antibody response in approximately 30-50% of patients undergoing CPB, and precipitating heparin-induced thrombocytopenia and thrombosis syndrome (HITTS) in 1-3% of patients [13,14,20,[23][24][25][26]. HIT is a limb and life-threatening complication of therapy with a mortality rate approaching 40%, [25] and though venous thrombosis is the most common clinical presentation, arterial thrombosis, including ischemic stroke and acute graft closure is not rare [26].…”

Section: Unfractionated Heparinmentioning

confidence: 99%

Anticoagulant therapy during cardiopulmonary bypass

Yavari

Becker

2008

J Thromb Thrombolysis

View full text Add to dashboard Cite

The prothrombotic and hemostatic-altering environment that characterizes cardiac surgery in general and cardiopulmonary bypass (CPB) in particular is unparalleled in medicine, causing, in an alarming number of patients, both thrombotic and hemorrhagic events. Fundamentally, the primary objective of anticoagulant therapy during CPB is to prevent thrombin generation and its attendant prothrombotic, proinflammatory, and vascular effects. Though anticoagulation with unfractionated heparin has been the standard of care for more than a half-century for patients undergoing cardiac surgery, inherent limitations, and an unfavorable safety profile will increasingly stimulate the investigation and development of more safe and effective therapies.

show abstract

Heparin, Platelet Aggregation, Neutrophils, and Cardiopulmonary Bypass

Cited by 31 publications

References 21 publications

Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry

Platelet concentrates transfusion in cardiac surgery and platelet function assessment by multiple electrode aggregometry

Post‐operative volume therapy in cardiac surgery: effects on hemostatic and circulatory variables

Anticoagulant therapy during cardiopulmonary bypass

Contact Info

Product

Resources

About